Eton Pharmaceuticals (NASDAQ:ETON) released its earnings results on Tuesday. The company reported ($0.42) EPS for the quarter, Morningstar.com reports. The firm had revenue of $0.50 million for the quarter.
Shares of ETON stock traded down $0.06 during mid-day trading on Wednesday, hitting $7.64. The company had a trading volume of 34,700 shares, compared to its average volume of 24,674. Eton Pharmaceuticals has a 52-week low of $5.70 and a 52-week high of $8.11.
A hedge fund recently bought a new stake in Eton Pharmaceuticals stock. Apollo Management Holdings L.P. bought a new position in Eton Pharmaceuticals Inc (NASDAQ:ETON) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 90,000 shares of the company’s stock, valued at approximately $551,000. Apollo Management Holdings L.P. owned approximately 0.51% of Eton Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 6.54% of the company’s stock.
About Eton Pharmaceuticals
Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical product using the U.S. Food and Drug Administration's 505(b)(2) regulatory pathway. It primarily focuses on liquid products, including injectable, oral liquid, and ophthalmic products.
Featured Article: How do candlesticks reflect price movement?